A Phase 3 interventional study of CD5789 (trifarotene) in Acne Vulgaris, sponsored by Galderma R&D. Completed at 32 sites in 4 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2019-11-14.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.
Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 7th largest by enrollment, is one of 3 that started in 2015, is one of 6 in phase 3, and was the 2nd registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2015.
This study's enrollment of 453 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 507 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 11th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2015, is one of 20 in phase 3, and was the 33rd registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
1 of the studies testing trifarotene in Acne Vulgaris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing trifarotene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.
To determine the safety and efficacy of CD5789 (trifarotene) 50 µg/g cream in the long-term treatment (up to 52 Weeks) of subjects with acne vulgaris. Efficacy will be evaluated as a secondary objective.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Drug: CD5789 (trifarotene)
Investigator Global Assessment (IGA) Success Rate up to Week 52
Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (clear).
Time frame: From Baseline to Week 52
Physician Global Assessment (PGA) Success Rate up to Week 52
Number of subjects who achieved a Physician Global Assessment (PGA) score of 1 (almost clear) or 0 (clear).
Time frame: From Baseline to Week 52
| Milestone | CD5789 Cream |
|---|---|
| Started | 453 |
| Completed | 348 |
| Not completed | 105 |
Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (clear).
| Participants | CD5789 Cream |
|---|---|
| Investigator Global Assessment (IGA) Success Rate up to Week 52 | 453 |
Number of subjects who achieved a Physician Global Assessment (PGA) score of 1 (almost clear) or 0 (clear).
| Participants | CD5789 Cream |
|---|---|
| Physician Global Assessment (PGA) Success Rate up to Week 52 | 453 |
Collected over Over 52 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD5789 Cream | 0/453 (0%) | 10/453 (2.2%) | 170/453 (37.5%) |
| Event | CD5789 Cream |
|---|---|
| Crohn's DiseaseGastrointestinal disorders | 1/453 |
| Umbilical HerniaGastrointestinal disorders | 1/453 |
| AppendicitisInfections and infestations | 1/453 |
| Pyelonephritis AcuteInfections and infestations | 1/453 |
| Complex partial seizuresNervous system disorders | 1/453 |
| Complex regional Pain syndromeNervous system disorders | 1/453 |
| Nasal septum deviationRespiratory, thoracic and mediastinal disorders | 1/453 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 1/453 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/453 |
| Liver function test abnormalInvestigations | 1/453 |
| Event | CD5789 Cream |
|---|---|
| NasopharyngitisInfections and infestations | 48/453 |
| SunburnInjury, poisoning and procedural complications | 27/453 |
| Application Site PruritisGeneral disorders | 23/453 |
| Application Site IrritationGeneral disorders | 22/453 |
| Upper Respiratory Tract InfectionInfections and infestations | 13/453 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 9/453 |
| InfluenzaInfections and infestations | 9/453 |
| Ligament SprainInjury, poisoning and procedural complications | 6/453 |
| HeadacheNervous system disorders | 6/453 |
| DiarrheaGastrointestinal disorders | 5/453 |
A total of 455 subjects were enrolled and 453 were exposed to CD5789 50 microgram/gram cream for up to 52 weeks.
| Age, Categorical(Participants) | CD5789 Cream |
|---|---|
| <=18 years | 286 |
| Between 18 and 65 years | 167 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | CD5789 Cream |
|---|---|
| Female | 226 |
| Male | 227 |
| Ethnicity (NIH/OMB)(Participants) | CD5789 Cream |
|---|---|
| Hispanic or Latino | 47 |
| Not Hispanic or Latino | 406 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | CD5789 Cream |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 3 |
| Black or African American | 12 |
| White | 432 |
| More than one race | 2 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | CD5789 Cream |
|---|---|
| Hungary | 91 |
| United States | 163 |
| Czechia | 104 |
| Germany | 95 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Feb 2017, 24 months.
Results were first posted in Sep 2019, 2 years 6 months after primary completion. A results delay was requested in May 2018.
Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 24 months is above that.
Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trifarotene